seed
Stage
1
Investors
About
Alys Pharmaceuticals develops immuno-dermatology therapeutics by consolidating assets from multiple companies into a research-driven pipeline targeting dermatologic conditions, including programs advancing to clinical trials like a mast cell selective c-Kit inhibitor for Chronic Urticaria.
Explore Alys Pharmaceuticals's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.